153 related articles for article (PubMed ID: 22269828)
1. Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).
Zarogiannis SG; Noah JW; Jurkuvenaite A; Steele C; Matalon S; Noah DL
Life Sci; 2012 Mar; 90(11-12):440-5. PubMed ID: 22269828
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice.
Paukner S; Kimber S; Cumper C; Rea-Davies T; Sueiro Ballesteros L; Kirkham C; Hargreaves A; Gelone SP; Richards C; Wicha WW
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791439
[TBL] [Abstract][Full Text] [Related]
3. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
Smee DF; Wong MH; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2006; 17(4):185-92. PubMed ID: 17066897
[TBL] [Abstract][Full Text] [Related]
4. Utilization of alpha-1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors.
Sidwell RW; Wong MH; Bailey KW; Barnard DL; Jackson MK; Smee DF
Antivir Chem Chemother; 2001 Nov; 12(6):359-65. PubMed ID: 12018681
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
Tanaka A; Nakamura S; Seki M; Iwanaga N; Kajihara T; Kitano M; Homma T; Kurihara S; Imamura Y; Miyazaki T; Izumikawa K; Kakeya H; Yanagihara K; Kohno S
Antivir Ther; 2015; 20(1):11-9. PubMed ID: 24517996
[TBL] [Abstract][Full Text] [Related]
6. The immuno-regulatory impact of orally-administered Hypericum perforatum extract on Balb/C mice inoculated with H1n1 influenza A virus.
Huang N; Singh N; Yoon K; Loiacono CM; Kohut ML; Birt DF
PLoS One; 2013; 8(9):e76491. PubMed ID: 24098792
[TBL] [Abstract][Full Text] [Related]
7. Anti-IFN-γ therapy alleviates acute lung injury induced by severe influenza A (H1N1) pdm09 infection in mice.
Liu B; Bao L; Wang L; Li F; Wen M; Li H; Deng W; Zhang X; Cao B
J Microbiol Immunol Infect; 2021 Jun; 54(3):396-403. PubMed ID: 31780358
[TBL] [Abstract][Full Text] [Related]
8. Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration.
Jia X; Liu B; Bao L; Lv Q; Li F; Li H; An Y; Zhang X; Cao B; Wang C
PLoS Pathog; 2018 Nov; 14(11):e1007428. PubMed ID: 30422993
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
10. In vivo ribavirin activity against severe pandemic H1N1 Influenza A/Mexico/4108/2009.
Rowe T; Banner D; Farooqui A; Ng DC; Kelvin AA; Rubino S; Huang SS; Fang Y; Kelvin DJ
J Gen Virol; 2010 Dec; 91(Pt 12):2898-906. PubMed ID: 20797971
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
Nguyen JT; Smee DF; Barnard DL; Julander JG; Gross M; de Jong MD; Went GT
PLoS One; 2012; 7(1):e31006. PubMed ID: 22292088
[TBL] [Abstract][Full Text] [Related]
12. Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine.
Smee DF; Wandersee MK; Wong MH; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2004 Sep; 15(5):261-8. PubMed ID: 15535048
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
[TBL] [Abstract][Full Text] [Related]
14. Impaired wound healing predisposes obese mice to severe influenza virus infection.
O'Brien KB; Vogel P; Duan S; Govorkova EA; Webby RJ; McCullers JA; Schultz-Cherry S
J Infect Dis; 2012 Jan; 205(2):252-61. PubMed ID: 22147799
[TBL] [Abstract][Full Text] [Related]
15. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
[TBL] [Abstract][Full Text] [Related]
17. Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus.
Wang C; Liu P; Luo J; Ding H; Gao Y; Sun L; Luo F; Liu X; He H
Front Cell Infect Microbiol; 2017; 7():267. PubMed ID: 28664154
[TBL] [Abstract][Full Text] [Related]
18. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.
Baz M; Abed Y; Nehmé B; Boivin G
Antimicrob Agents Chemother; 2009 Feb; 53(2):791-3. PubMed ID: 19015327
[TBL] [Abstract][Full Text] [Related]
19. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
20. Polygalasaponin F treats mice with pneumonia induced by influenza virus.
Ye Y; Wang H; Liu J; Zhao F; Xu P
Inflammopharmacology; 2020 Feb; 28(1):299-310. PubMed ID: 31446589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
